Loading clinical trials...
Loading clinical trials...
Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by by Percutaneous Ablation Procedure in Curative Intent: French Multicenter Phase 2 Therapeutic
Conditions
Interventions
Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting
Locations
1
France
Hospitl Avicenne
Bobigny, France
Start Date
March 28, 2024
Primary Completion Date
September 27, 2027
Completion Date
September 27, 2028
Last Updated
April 24, 2026
NCT07285850
NCT07106827
NCT06999837
NCT07141056
NCT07132515
NCT06999707
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions